Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter, postoperative, randomized controlled, open label, phase II clinical trial of recombinant human endostatin on vascular normalization for esophageal squamous cell carcinoma

Next Previous
Trial Profile

Multicenter, postoperative, randomized controlled, open label, phase II clinical trial of recombinant human endostatin on vascular normalization for esophageal squamous cell carcinoma

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Jun 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Endostatin (Primary)
  • Indications Oesophageal cancer; Squamous cell cancer
  • Focus Therapeutic Use

Most Recent Events

  • 13 Jul 2015 New trial record
  • 02 Jun 2015 Primary endpoint has been met. (overall survival), according to an abstract presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
  • 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top